About Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals is engaged in contract manufacturing which involves manufacturing of pharmaceutical formulations and specializes in developing new formulations, undertaking bio equivalence studies, clinical trials, obtaining Drug Controller General of India's (DCGI) approval for manufacturing and marketing new Fixed Dose Combinations (FDCs) & molecules and thereby offering new formulations with Company's own technology to its customers under their brand names.(Source : AR-PDF:202603-01 Pg No:223)
Founded
2004
CEO
N/A
Employees
18,010
HQ
Delhi, Delhi
Finished Products
1Sale of Products
₹4,974.10Cr2Sale of Services
₹1,357.80Cr3Other Operating Revenue
₹221.63CrRaw Materials
1Raw Materials Consumed
₹4,086.35CrAbout Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals is engaged in contract manufacturing which involves manufacturing of pharmaceutical formulations and specializes in developing new formulations, undertaking bio equivalence studies, clinical trials, obtaining Drug Controller General of India's (DCGI) approval for manufacturing and marketing new Fixed Dose Combinations (FDCs) & molecules and thereby offering new formulations with Company's own technology to its customers under their brand names.(Source : AR-PDF:202603-01 Pg No:223)
Founded:2004
CEO:N/A
Employees:18,010
HQ:Delhi, Delhi
Finished Products
1Sale of Products
₹4,974.10Cr2Sale of Services
₹1,357.80Cr3Other Operating Revenue
₹221.63CrRaw Materials
1Raw Materials Consumed
₹4,086.35CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹797
52W Low
₹409
Volume750.07K
Avg VolumeN/A
Beta0.93
Dividend Yield0.37%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
41.88x
Valuation
P/B Ratio
3.70x
Valuation
EPS
₹18.60
Valuation
Dividend Yield
0.37%
Valuation
ROE
7.70%
Profitability
ROCE
10.95%
Profitability
Revenue by Segment
Contribution & growth by business line
CDMO
-5.0%78.0%
₹3,440.24 Cr
Domestic Branded formulations
+8.8%9.8%
₹433.59 Cr
API
-0.5%6.3%
₹277.12 Cr
International Branded Formulations
+14.3%3.2%
₹142.61 Cr
Trade generics
-33.3%2.7%
₹117.88 Cr
Geographical Revenue Split
Domestic vs international exposure
Domestic
0.0%
International
0.0%
No geographic split data available
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.05x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
1.4%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.